The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Videos|May 29, 2020
How to address patient concerns during COVID-19
Author(s)Jessica Barry
Dermatology patients are hungry for information that will ensure their safety during the COVID-19 pandemic, notes Vivian Shi, M.D. In this video, she discusses how to address patients' varying concerns in this uncertain time.
Advertisement
Dermatology patients are hungry for information that will ensure their safety during the COVID-19 pandemic, notes Vivian Shi, M.D. In this video, she discusses how to address patients' varying concerns in this uncertain time.
Advertisement
Related to this article
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5